Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors


The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

Study Start Date

May, 26 2017

Estimated Completion Date

March 2020


  • Drug: TNO155

Study ID

Novartis -- CTNO155X2101



Trial ID


Study Type


Trial Phase

Phase 1

Enrollment Quota




Inclusion Criteria

    1. Able to understand and voluntarily sign the ICF and able to comply with the study visit schedule and the other protocol requirements. 2. Patient (male or female) ?18 years of age willing to agree to not father a child/become pregnant and comply with effective contraception criteria. 3. Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or is appropriate. 4. ECOG (Eastern cooperative oncology group) performance status ?2

Exclusion Criteria

    1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations. 2. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. 3. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. 4. Clinically significant cardiac disease. 5. Active diarrhea or inflammatory bowel disease 6. Insufficient bone marrow function 7. Insufficient hepatic and renal function.




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (3)

Study Location Distance Name Phone Email
Dana Farber Cancer Center - Boston, Massachusetts 2.4 miles Beth Meyers 617-643-1820
Memorial Sloan Kettering Cancer Center - New York, New York 187.1 miles Murielle Georges 656-888-4563
Memorial Sloan Kettering Cancer Center - New York, New York 187.1 miles Murielle Georges 656-888-4563 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.